ClinicalTrials HQ

Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant

Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant

Recruiting · NCT06938867 · Registry updated 2026-10-08
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-TransplantBacterial Infections and Mycoses, Enterobacteriaceae Infections, Infections, bacterial infectious disease, escherichia coli infection, gram-negative bacterial infectionsRecruitingPhase 1 / Phase 22026-10-08NCT06938867

7 results · Page 1 of 1

10 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
City of HopeDuarteUnited States238
Dana Farber Cancer InstituteBostonUnited States300
Fred Hutchinson Cancer CenterSeattleUnited States250
Johns Hopkins UniversityBaltimoreUnited States49
Memorial Sloan Kettering Cancer CenterNew YorkUnited States1000
University of California, San FranciscoSan FranciscoUnited States3
University of MinnesotaMinneapolisUnited States325
University of Texas MD Anderson Cancer CenterHoustonUnited States192
UPMCPittsburghUnited States1
Weill Cornell MedicineNew YorkUnited States122